Selected research
Industry Research
Rare Disease Pharmaceutical Service Industry Research Report 2026
Market perspective
The global Rare Disease Pharmaceutical Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Rare Disease Pharmaceutical Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Rare Disease Pharmaceutical Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Rare Disease Pharmaceutical Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Rare Disease Pharmaceutical Service include Ultragenyx, Chiesi, Sciensus, Abbvie, Orpharma, Amgen, Recordati, Novartis and Celgene, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Rare Disease Pharmaceutical Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Rare Disease Pharmaceutical Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rare Disease Pharmaceutical Service Market by Company
Ultragenyx
Chiesi
Sciensus
Abbvie
Orpharma
Amgen
Recordati
Novartis
Celgene
Amryt Pharma
Johnson & Johnson
GSK
Shire
Merck
Pfizer
Biogen
Sanofi
AstraZeneca
Takeda
Rare Disease Pharmaceutical Service Segment by Type
Drug Discovery
Clinical Trials
Others
Rare Disease Pharmaceutical Service Segment by Application
Congenital and Genetic Diseases
Tumors and Cancer
Endocrine Diseases
Others
Rare Disease Pharmaceutical Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Pharmaceutical Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Pharmaceutical Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Pharmaceutical Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Rare Disease Pharmaceutical Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drug Discovery
- Clinical Trials
- Others
Applications
- Congenital and Genetic Diseases
- Tumors and Cancer
- Endocrine Diseases
- Others
Companies covered
- Ultragenyx
- Chiesi
- Sciensus
- Abbvie
- Orpharma
- Amgen
- Recordati
- Novartis
- Celgene
- Amryt Pharma
- Johnson & Johnson
- GSK
- Shire
- Merck
- Pfizer
- Biogen
- Sanofi
- AstraZeneca
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Rare Disease Pharmaceutical Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drug Discovery
- 2.2.3 Clinical Trials
- 2.2.4 Others
- 2.3 Rare Disease Pharmaceutical Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Congenital and Genetic Diseases
- 2.3.3 Tumors and Cancer
- 2.3.4 Endocrine Diseases
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Rare Disease Pharmaceutical Service Breakdown Data by Type
- 3.1 Global Rare Disease Pharmaceutical Service Historic Market Size by Type (2021-2026)
- 3.2 Global Rare Disease Pharmaceutical Service Forecasted Market Size by Type (2027-2032)
4 Rare Disease Pharmaceutical Service Breakdown Data by Application
- 4.1 Global Rare Disease Pharmaceutical Service Historic Market Size by Application (2021-2026)
- 4.2 Global Rare Disease Pharmaceutical Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Rare Disease Pharmaceutical Service Market Perspective (2021-2032)
- 5.2 Global Rare Disease Pharmaceutical Service Growth Trends by Region
- 5.2.1 Global Rare Disease Pharmaceutical Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Rare Disease Pharmaceutical Service Historic Market Size by Region (2021-2026)
- 5.2.3 Rare Disease Pharmaceutical Service Forecasted Market Size by Region (2027-2032)
- 5.3 Rare Disease Pharmaceutical Service Market Dynamics
- 5.3.1 Rare Disease Pharmaceutical Service Industry Trends
- 5.3.2 Rare Disease Pharmaceutical Service Market Drivers
- 5.3.3 Rare Disease Pharmaceutical Service Market Challenges
- 5.3.4 Rare Disease Pharmaceutical Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Rare Disease Pharmaceutical Service Players by Revenue
- 6.1.1 Global Top Rare Disease Pharmaceutical Service Players by Revenue (2021-2026)
- 6.1.2 Global Rare Disease Pharmaceutical Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Rare Disease Pharmaceutical Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Rare Disease Pharmaceutical Service Head Office and Area Served
- 6.4 Global Rare Disease Pharmaceutical Service Players, Product Type & Application
- 6.5 Global Rare Disease Pharmaceutical Service Manufacturers Established Date
- 6.6 Global Rare Disease Pharmaceutical Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 7.2 North America Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 7.4 North America Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 8.2 Europe Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 8.4 Europe Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 9.2 Asia-Pacific Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 10.2 South America Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 10.4 South America Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Rare Disease Pharmaceutical Service Market Size (2021-2032)
- 11.2 Middle East & Africa Rare Disease Pharmaceutical Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Rare Disease Pharmaceutical Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Ultragenyx
- 12.1.1 Ultragenyx Company Information
- 12.1.2 Ultragenyx Business Overview
- 12.1.3 Ultragenyx Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.1.4 Ultragenyx Rare Disease Pharmaceutical Service Product Portfolio
- 12.1.5 Ultragenyx Recent Developments
- 12.2 Chiesi
- 12.2.1 Chiesi Company Information
- 12.2.2 Chiesi Business Overview
- 12.2.3 Chiesi Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.2.4 Chiesi Rare Disease Pharmaceutical Service Product Portfolio
- 12.2.5 Chiesi Recent Developments
- 12.3 Sciensus
- 12.3.1 Sciensus Company Information
- 12.3.2 Sciensus Business Overview
- 12.3.3 Sciensus Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.3.4 Sciensus Rare Disease Pharmaceutical Service Product Portfolio
- 12.3.5 Sciensus Recent Developments
- 12.4 Abbvie
- 12.4.1 Abbvie Company Information
- 12.4.2 Abbvie Business Overview
- 12.4.3 Abbvie Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.4.4 Abbvie Rare Disease Pharmaceutical Service Product Portfolio
- 12.4.5 Abbvie Recent Developments
- 12.5 Orpharma
- 12.5.1 Orpharma Company Information
- 12.5.2 Orpharma Business Overview
- 12.5.3 Orpharma Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.5.4 Orpharma Rare Disease Pharmaceutical Service Product Portfolio
- 12.5.5 Orpharma Recent Developments
- 12.6 Amgen
- 12.6.1 Amgen Company Information
- 12.6.2 Amgen Business Overview
- 12.6.3 Amgen Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.6.4 Amgen Rare Disease Pharmaceutical Service Product Portfolio
- 12.6.5 Amgen Recent Developments
- 12.7 Recordati
- 12.7.1 Recordati Company Information
- 12.7.2 Recordati Business Overview
- 12.7.3 Recordati Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.7.4 Recordati Rare Disease Pharmaceutical Service Product Portfolio
- 12.7.5 Recordati Recent Developments
- 12.8 Novartis
- 12.8.1 Novartis Company Information
- 12.8.2 Novartis Business Overview
- 12.8.3 Novartis Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.8.4 Novartis Rare Disease Pharmaceutical Service Product Portfolio
- 12.8.5 Novartis Recent Developments
- 12.9 Celgene
- 12.9.1 Celgene Company Information
- 12.9.2 Celgene Business Overview
- 12.9.3 Celgene Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.9.4 Celgene Rare Disease Pharmaceutical Service Product Portfolio
- 12.9.5 Celgene Recent Developments
- 12.10 Amryt Pharma
- 12.10.1 Amryt Pharma Company Information
- 12.10.2 Amryt Pharma Business Overview
- 12.10.3 Amryt Pharma Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.10.4 Amryt Pharma Rare Disease Pharmaceutical Service Product Portfolio
- 12.10.5 Amryt Pharma Recent Developments
- 12.11 Johnson & Johnson
- 12.11.1 Johnson & Johnson Company Information
- 12.11.2 Johnson & Johnson Business Overview
- 12.11.3 Johnson & Johnson Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.11.4 Johnson & Johnson Rare Disease Pharmaceutical Service Product Portfolio
- 12.11.5 Johnson & Johnson Recent Developments
- 12.12 GSK
- 12.12.1 GSK Company Information
- 12.12.2 GSK Business Overview
- 12.12.3 GSK Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.12.4 GSK Rare Disease Pharmaceutical Service Product Portfolio
- 12.12.5 GSK Recent Developments
- 12.13 Shire
- 12.13.1 Shire Company Information
- 12.13.2 Shire Business Overview
- 12.13.3 Shire Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.13.4 Shire Rare Disease Pharmaceutical Service Product Portfolio
- 12.13.5 Shire Recent Developments
- 12.14 Merck
- 12.14.1 Merck Company Information
- 12.14.2 Merck Business Overview
- 12.14.3 Merck Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.14.4 Merck Rare Disease Pharmaceutical Service Product Portfolio
- 12.14.5 Merck Recent Developments
- 12.15 Pfizer
- 12.15.1 Pfizer Company Information
- 12.15.2 Pfizer Business Overview
- 12.15.3 Pfizer Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.15.4 Pfizer Rare Disease Pharmaceutical Service Product Portfolio
- 12.15.5 Pfizer Recent Developments
- 12.16 Biogen
- 12.16.1 Biogen Company Information
- 12.16.2 Biogen Business Overview
- 12.16.3 Biogen Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.16.4 Biogen Rare Disease Pharmaceutical Service Product Portfolio
- 12.16.5 Biogen Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.17.4 Sanofi Rare Disease Pharmaceutical Service Product Portfolio
- 12.17.5 Sanofi Recent Developments
- 12.18 AstraZeneca
- 12.18.1 AstraZeneca Company Information
- 12.18.2 AstraZeneca Business Overview
- 12.18.3 AstraZeneca Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.18.4 AstraZeneca Rare Disease Pharmaceutical Service Product Portfolio
- 12.18.5 AstraZeneca Recent Developments
- 12.19 Takeda
- 12.19.1 Takeda Company Information
- 12.19.2 Takeda Business Overview
- 12.19.3 Takeda Revenue in Rare Disease Pharmaceutical Service Business (2021-2026)
- 12.19.4 Takeda Rare Disease Pharmaceutical Service Product Portfolio
- 12.19.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst